GSK drug Jideytro shows competitive profile for label expansion
J.P. Morgan says GSK’s lung-cancer drug Jideytro data support a competitive profile for a potential label expansion next year, citing a delay in disease progression for 90% of patients with advanced lung cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.